1. Home
  2. |Insights
  3. |Litigation Note: Crowell & Moring Secures IP Victory for Watson Pharmaceuticals (now Actavis)

Litigation Note: Crowell & Moring Secures IP Victory for Watson Pharmaceuticals (now Actavis)

Firm News | less than 1 min read | 04.15.13

Washington, D.C. – April 15, 2013: Crowell & Moring represented Watson Pharmaceuticals, Inc. (now Actavis, Inc.) in successfully defending the patent infringement case brought by Bayer HealthCare Pharmaceuticals Inc. regarding its RE37,564 patent for the Yaz ® contraceptive. Today, the Federal Circuit reversed the adverse summary judgment decision made by the district court in March 2012 and held that Bayer's asserted patent claims were invalid. The court found that the cited prior art references set forth every limitation required by the asserted claims and provide express motivation to combine those teachings to derive the claimed oral contraceptive product. As a result of the decision today, Actavis has re-launched its generic product.


Insights

Firm News | 3 min read | 03.04.26

Former Special Counsel to the FBI Director and Federal Prosecutor Rajeev Raghavan Joins Crowell & Moring’s Privacy & Cybersecurity Group

Washington, D.C. – March 4, 2026: Crowell & Moring has expanded its Privacy and Cybersecurity Group with the addition of Rajeev Raghavan, a former Special Counsel to the Director of the Federal Bureau of Investigation and federal prosecutor. With more than 15 years of direct experience handling cybercrime, technology, regulatory, and enforcement challenges, and a foundational background as a computer programmer, Raghavan further strengthens the firm’s ability to help clients respond to evolving cybersecurity threats and navigate a rapidly changing legal and regulatory environment....